Swedish Orphan Biovitrum AB (publ) : Sobi receives EMA approval to manufacture Kineret® drug substance with partner Boehringer

Swedish Orphan Biovitrum AB (publ) : Sobi receives EMA approval to manufacture
          Kineret® drug substance with partner Boehringer Ingelheim

Ingelheim, Germany/Stockholm, Sweden, 23 February 2013 - Sobi (STO: SOBI)
announced receipt of approval from the European Medicines Agency (EMA) for the
manufacture of drug substance for Kineret® (anakinra) at Boehringer
Ingelheim's microbial site in Vienna, Austria. The approval allows for
distribution of Kineret to EMA territory countries, and comes as the result of
an application filed with the EMA in October of 2012. A similar application
has been filed with the US FDA and authorities in other countries where
Kineret is approved.

Geoff McDonough, CEO of Sobi states, "This marks an important milestone in the
process of technology transfer of Kineret manufacturing from Amgen to
Boehringer Ingelheim. We are pleased with the progress we are making with our
partners in this regard."

"Kineret is an important commercial product for both companies. We have
already started to ramp up manufacturing to ensure reliable supply to the
market", stated Dr. Lothar Halmer, Site Head Biopharma Austria at Boehringer
Ingelheim RCV GmbH & Co KG.

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical
companies with net sales of about 13.2 billion Euros in 2011. Since it was
founded in 1885, the family-owned company has been committed to researching,
developing, manufacturing and marketing novel medications of high therapeutic
value for human and veterinary medicine.

All activities of the biopharmaceutical contract manufacturing are performed
within the Boehringer Ingelheim Biopharmaceuticals GmbH, headquartered in
Ingelheim, Germany and are represented by its new brand Boehnger Ingelheim
BioXcellence(TM). As a leading biopharmaceutical contract manufacturer with
more than 35 years of experience - the company has brought more than 20
biopharmaceutical products to market. Boehringer Ingelheim BioXcellence(TM)
offers tailor-made contract development and manufacturing services to the
biopharmaceutical industry, providing the entire production technology chain
from DNA to fill and finish under one roof at its facilities in Biberach
(Germany), Vienna (Austria) and Fremont (USA). Boehringer Ingelheim
BioXcellence(TM) can secure product supply throughout the entire product
lifecycle-transferring customer projects at any stage, delivering to almost
any scale and thereby makes outsourcing easy.

About Kineret® (anakinra)

Kineret is a recombinant protein drug approved for the treatment of children
and adults with NOMID, and the reduction in signs and symptoms and slowing the
progression of structural damage in moderately to severely active rheumatoid
arthritis (RA), in patients 18 years of age or older who have failed one or
more disease modifying antirheumatic drugs (DMARDs). Kineret blocks the
biological activity of IL-1 by binding to the interleukin-1 type 1 receptor,
expressed in a wide variety of tissues and organs. IL-1 is a key mediator of
inflammation and driver of autoinflammatory diseases in both adults and
children. For more information on Kineret see the Prescribing Information.
(www.kineretrx.com)

About Sobi

Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on inflammation and genetic diseases, with three late stage biological
development projects within hemophilia and neonatology. We also market more
than 40 specialty and rare disease products for partner companies. Sobi is a
pioneer in biotechnology with world-class capabilities in protein biochemistry
and biologics manufacturing. In 2011, Sobi had total revenues of SEK 1.9
billion (€ 214 M) and about 500 employees. The share (STO: SOBI) is listed on
NASDAQ OMX Stockholm. More information is available at www.sobi.com

Contact at Boehringer Ingelheim:
Heidrun Thoma
Corporate Communications
Boehringer Ingelheim GmbH
55216 Ingelheim/Germany
Phone: +49/6132 77 3966
Heidrun.Thoma@boehringer-ingelheim.com
Twitter: www.twitter.com/boehringer 

More information:
www.bioxcellence.com
bioxcellence@boehringer-ingelheim.com

Contact at Sobi:
Birgitte Volck, Senior Vice President Development, Chief Medical Officer
Phone: +46 8 697 20 94



Sobi Press Release on January 22, 2013, in PDF format

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE
HUG#1672314
 
Press spacebar to pause and continue. Press esc to stop.